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Abstract: Clostridium perfringens enterotoxin (CPE) is responsible for causing the gastrointestinal
symptoms of several C. perfringens food- and nonfood-borne human gastrointestinal diseases. The
enterotoxin gene (cpe) is located on either the chromosome (for most C. perfringens type A food
poisoning strains) or large conjugative plasmids (for the remaining type A food poisoning and
most, if not all, other CPE-producing strains). In all CPE-positive strains, the cpe gene is strongly
associated with insertion sequences that may help to assist its mobilization and spread. During
disease, CPE is produced when C. perfringens sporulates in the intestines, a process involving several
sporulation-specific alternative sigma factors. The action of CPE starts with its binding to claudin
receptors to form a small complex; those small complexes then oligomerize to create a hexameric
prepore on the membrane surface. Beta hairpin loops from the CPE molecules in the prepore assemble
into a beta barrel that inserts into the membrane to form an active pore that enhances calcium influx,
causing cell death. This cell death results in intestinal damage that causes fluid and electrolyte loss.
CPE is now being explored for translational applications including cancer therapy/diagnosis, drug
delivery, and vaccination.
Keywords: Clostridium perfringens; enterotoxin; pore-forming toxin; sporulation; tight
junctions; claudins
1. Introduction
Clostridium perfringens is a preeminent pathogen of humans and livestock, causing both histotoxic
diseases and illnesses originating in the intestines, namely enteritis or enterotoxemia (where toxins
produced in the intestine are absorbed into the circulation and then damage organs such as the
brain) [1]. The virulence of this Gram-positive, spore-forming anaerobe is largely attributable to its
ability to produce at least 17 different toxins [2]. However, there is considerable variability in the
toxin armamentarium of different C. perfringens strains, which provides the basis for a toxinotyping
classification system that divides C. perfringens isolates into five types (A–E) depending upon their
ability to produce alpha, beta, epsilon, and iota toxin [2].
About 5% of all C. perfringens isolates produce a toxin named C. perfringens enterotoxin (CPE) [3].
Most CPE-positive strains classify as type A, although types C and D strains producing this enterotoxin
are also fairly common [4]. The primary amino acid sequence of the CPE protein made by CPE-positive
types A, C, and D strains is virtually identical [4]. It had been thought that type E strains only carry
silent cpe sequences [5], but a recent study identified a few type E strains that produce a variant CPE [6].
To date, there are no reliable reports of CPE production by type B strains.
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2. The Importance of CPE in Gastrointestinal (GI) Disease
Clostridium perfringens type A food poisoning ranks as the second most common foodborne illness
in most developed countries [7]. For example, there are approximately one million cases of this
food poisoning each year in the United States, causing annual economic losses of ~$400 million [8,9].
Compelling epidemiologic and experimental evidence indicates that CPE is the toxin responsible for the
diarrhea and abdominal cramping symptoms that are characteristic of type A food poisoning [7]. The
most persuasive laboratory evidence linking CPE to this foodborne illness was provided by a study [10]
reporting that inactivation of the cpe gene in a human food poisoning strain renders that strain avirulent
in animal models of enteric disease, with this attenuation reversible by complementation to restore
CPE production (Figure 1). One example of the abundant epidemiologic evidence supporting a role for
CPE in C. perfringens type A food poisoning is the direct detection of CPE in feces from most patients
with this foodborne illness [7].
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Figure 1. Histologic damage induced by lysates of CPE-positive type A strain SM101, a 
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sections from rabbit ileal loops treated with concentrated vegetative culture lysates (FTG) or 
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null mutant of SM101) or a complementing strain where the cpe gene has been transformed back 
into MRS101. Note the complete absence of damage using lysates of SM101 vegetative cultures or 
DS cultures of the MRS101 cpe null mutant. However, extensive necrosis, villus damage, and 
epithelial desquamation were observed using lysates of the DS culture of wild-type SM101 or the 
complementing strain. Samples shown are at 250 × magnification. Reproduced with permission 
from [10]. 
It deserves brief mention that two studies recently linked CPE-negative type A strains to some 
food poisoning cases in Japan [11,12]. However, the responsible toxin made by those strains 
resembles iota toxin, so those cases might better be considered as type E human food poisoning. 
The prevalence of these new type E-like strains in human food poisoning requires further study, 
but it seems clear that CPE-positive type A strains are responsible for the great majority of human 
food poisoning cases caused by C. perfringens. 
Figure 1. Histologic damage induced by lysates of CPE-positive type A strain SM101, a transformable
food poisoning strain derivative. Shown are hematoxylin and eosin-stained tissue sections from rabbit
ileal loops treated with concentrated vegetative culture lysates (FTG) or concentrated Duncan-Strong
(DS) sporulating culture lysates of wild-type SM101, MRS101 (a cpe null mutant of SM101) or a
compleme ting strain where the c e gene has been transformed back into MRS101. Note the complete
absence of damag using lysat s of SM101 vegetativ cultures or DS cultures of th MRS101 cpe null
mutant. However, xtensive ne rosis, villus damage, and pithelial desquamation were observed usi g
lysates of th DS culture of wild-type SM101 or the complementing strain. Samples shown are at 250 ˆ
magnification. Reproduced with permission from [10].
It deserves brief mention that two studies recently linked CPE-negative type A strains to some
food poisoning cases in Japan [11,12]. However, the responsible toxin made by those strains resembles
iota toxin, so those cases might better be considered as type E human food poisoning. The prevalence
of these new type E-like strains in human food poisoning requires further study, but it seems clear
that CPE-positive type A strains are responsible for the great majority of human food poisoning cases
caused by C. perfringens.
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In the past decade two unusually severe outbreaks of C. perfringens type A food poisoning occurred
that resulted in the deaths of several relatively young and healthy people [13,14]. These outbreaks
occurred in psychiatric hospitals and involved patients receiving psychoactive drugs, which often
have constipation or fecal impaction side-effects. It is believed that those side-effects interfered with
the development of the diarrhea typical of most C. perfringens type A food poisoning cases. Reducing
diarrhea would cause prolonged contact between the intestines and toxins like CPE, which may have
facilitated the absorption of CPE into the circulation so it could damage non-intestinal organs. This
hypothesis received direct experimental support from mouse studies demonstrating absorption of
CPE from static small intestinal loops [15]. The absorbed CPE then bound to the liver and kidneys,
producing an enterotoxemia that resulted in organ damage causing hyperpotassemia, which induced
death by cardiac arrest in mice.
In addition to C. perfringens type A food poisoning, CPE-positive type A strains also cause
several non-food-borne human gastrointestinal diseases, including about 5%–10% of all cases
of antibiotic-associated diarrhea [16]. Animal model studies [10] with cpe null mutants and
complementing strains of a CPE-positive non-food-borne human GI disease strain showed that CPE
production is required for the enteropathogenicity of these strains. Other evidence supporting the
importance of CPE for some cases of non-food-borne human GI disease cases includes the direct
detection of this toxin in feces from ~5% to 10% of people with these diseases [16].
CPE may also contribute to some cases of human enteritis necroticans (EN) caused by type C
strains. EN is a foodborne illness that is associated with low intestinal trypsin levels due to disease
and/or diet [2]. While beta toxin is clearly essential for the pathogenesis of EN, some type C strains
causing this disease also produce CPE [17]. Recent animal model studies [18] using toxin mutants
and purified toxins demonstrated synergistic effects for CPE and beta toxin, suggesting that (when
present together with beta toxin in the intestines) CPE can contribute to the pathogenesis of enteritis
necroticans. Whether CPE, when produced, contributes to type D disease is still unknown.
3. Introduction to the CPE Protein
Cloning of the cpe gene in 1993 [19] revealed that the CPE protein produced by a type A food
poisoning strain is a single polypeptide containing 319 amino acids with a unique primary sequence.
Later cpe nucleotide sequencing studies showed that the CPE produced by other CPE-positive type
A strains shares this same sequence [20], as does the CPE made by some type C and D strains of
C. perfringens [4]. Interestingly, a few type E strains produce a variant CPE with 10 amino acid
differences from the classical CPE made by types A, C, and D strains [6]. The phenotypic consequences
of those amino acid variations for toxicity are unknown at present.
There has been intensive analysis of the structure vs. function relationship for the CPE protein.
Early biochemical and cloning studies [21,22] determined that the C-terminal half of CPE lacks cytotoxic
activity, although it binds strongly to receptors. Synthetic peptide and subcloning approaches then
mapped strong receptor binding activity to the last 30 amino acids of the toxin [23]. Several tyrosine
residues in this extreme C-terminal region were later shown to be important for receptor binding [24,25].
More recent studies identified additional residues in the C-terminal half of CPE that also contribute to
receptor binding [26].
The first 44 amino acids of CPE are not necessary for cytotoxicity [27]. In fact, removing these
amino acids by deletion mutagenesis actually increases CPE cytotoxic activity by ~2–3 fold. This
effect likely has significance for CPE-mediated disease since the intestinal proteases trypsin and
chymotrypsin, which remove ~25 or 37 amino acids (respectively) from the N-terminus of native CPE,
also produce an activated toxin [28]. Note that these N-terminal sequences are not a signal peptide
since CPE is not secreted but instead accumulates inside a sporulating cell until that mother cell lyses
to release its spore (further discussion later).
Deletion of amino acids beyond amino acid 44 quickly abolishes CPE action [27]. Site-directed
mutagenesis studies [29] then identified several amino acids, particularly residues D48 and I51, in
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the N-terminal half of CPE as being extremely important for cytotoxicity because these amino acid
residues are needed for CPE oligomerization and pore formation.
However, oligomerization is not the only function mediated by the N-terminal half of CPE.
N-terminal CPE residues 80–106 (a region referred to as TM1) consist of alternating hydrophilic and
hydrophobic amino acids, which resemble the β-hairpin loops that are known to mediate membrane
insertion and pore formation for other bacterial pore-forming toxins [30]. Site-directed mutagenesis has
confirmed that this TM1 region is important for both CPE membrane insertion and pore formation [30].
In 2008, Van Itallie et al. [31] solved the structure of the C-terminal half of CPE (also referred to
as C-CPE). This structural analysis showed that the C-CPE domain is a nine-strand β-sandwich with
some resemblance to the receptor-binding domain of several other pore forming toxins. Amino acid
residues implicated in receptor binding form a pocket on the surface of C-CPE.
In 2010, the structure of the entire CPE protein was independently solved by two groups
(Figure 2A). Those studies [32,33] determined that CPE is a two-domain protein consisting of the
C-terminal receptor binding domain described above and a distinct N-terminal domain that is involved
in oligomerization and pore formation. The extreme N-terminus (residues 1–34) of CPE has no
interpretable density, which suggests disorder and may help to explain why these sequences, when
present, partially reduce CPE activity, i.e., they may sterically hinder oligomerization. The TM1 region
mediating membrane insertion and pore formation largely corresponds to an alpha helix located in the
N-terminal domain of CPE. This alpha helix likely unfolds into a β-hairpin loop during membrane
penetration and pore formation by the CH-1 complex [32,33].
Toxins 2016, 8, 73 4 of 16 
How ver, oligomerization is not the only functi n mediated by the N-terminal half of CPE. 
N-terminal CPE residues 80–106 (a region referred to as TM1) consist of alternating hydrophilic and 
hydrophobic amino acids, which resemble the β-hairpin loops that are known to mediate 
membrane inserti n and pore formation for ot er bacterial pore-forming toxins [30]. Site-directed 
mutagenesis has c nfirmed that t is TM1 region is important for both CPE m mbrane ins rtion and 
pore formation [30]. 
In 2008, Van Itallie et al. [31] solved the structure of the C-terminal half of CPE (also referred to 
as C-CPE). This structural nalysis showed that the C-CPE domain is a nine-strand β-sand ich 
with some resemblance to the receptor-binding domain f several ther pore forming toxins. 
Amino acid residues implicated in receptor binding f rm a pocket on the surface of C-CPE. 
In 2010, the structure of the entire CPE protein was independently solved by two groups 
(Figure 2A). Those studies [32,33] determined that CPE is a two-domain protein consisting of the 
C-terminal receptor binding domain described above and a distinct N-terminal domai  that is 
involved in oligomerization and pore formation. Th  extre e N-termin s (residues 1–34) of CPE 
has no interpr table density, which suggests disorder and may help to explain why these s quences, 
wh  present, partially reduce CPE activit , i.e., they may sterically hinder oligomerization. The 
TM1 region ediating membrane insertion and pore formation largely corresponds to an alpha 
helix loc te  in the N-terminal domain of CPE. This alpha helix likely unfolds into a β-hairpin loop 
during membrane penetratio  and pore formation by the CH-1 complex [32,33]. 
 
Figure 2. Structure of the CPE monomer (left) and C-CPE bound to a claudin receptor (right). Left 
panel (A) shows the two domain structure of the CPE monomer, consisting of the C-terminal CPE 
binding domain (C-CPE, yellow-red) and the N-terminal oligomerization/membrane insertion 
domain. Reproduced with permission from [32]. Right panel (B) shows the C-CPE binding domain 
bound to a claudin receptor, which consists of four transmembrane domains, two extracellular loops 
and a short C-terminal tail (not shown). Note that C-CPE interacts with both claudin extracellular 
loops but the second extracellular loop distinguishes claudins capable of binding CPE from those 
unable to bind the toxin. Reproduced with permission from [34]. 
Resolution of the CPE structure also assigned this toxin to the aerolysin pore-forming toxin 
family, which also includes (among other toxins) C. perfringens epsilon toxin [35]. Interestingly, CPE 
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formation is an alpha helix when CPE is in the soluble monomeric form. 
  
Figure 2. Structure of the CPE monomer (left) and C-CPE bound to a claudin receptor (right). Left
panel (A) shows the two domain structure of the CPE monomer, consisting of the C-terminal CPE
binding domain (C-CPE, yellow-red) and the N-terminal oligomerization/membran insertion domain.
Reproduced with permission f om [32]. Right panel (B) shows the C-CPE binding domain bound to a
cla din receptor, which consists of four transmembrane domains, two extracellular loops and a sh rt
C-terminal tail (not shown). N e that C-CPE in eracts with both claud n extrace lular loops but the
sec nd ex rac llular loop distinguishes claudins capable of binding CPE from those unable to bind the
toxin. Reproduced with permission from [34].
Resolution of the CPE structure also assigned this toxin to the aerolysin pore-forming toxin family,
which also includes (among other toxins) C. perfringens epsilon toxin [35]. Interestingly, CPE is unique
among members of this pore-forming toxin family since the region involved in β-hairpin formation is
an alpha helix when CPE is in the soluble monomeric form.
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4. cpe Genetics
Approximately 5% of global isolates produce CPE [3], which (as mentioned earlier) can be
encoded for by types A, C, D, and E strains of C. perfringens [4,6]. The enterotoxin gene (cpe) can be
located on either the chromosome or on plasmids [2]; no isolate has yet been found that carries both a
chromosomal and plasmid-borne cpe gene.
Most (~70%) type A food poisoning strains carry a chromosomal copy of the cpe gene [7]. This
chromosomal cpe gene is proximally associated with insertion sequences, including a IS1469 sequence
located 1.3 kb upstream of the cpe, gene and two IS1470 sequences, one of which is present 3 kb
upstream of the cpe gene and the other located 1.2 kb downstream of the cpe gene [36–38]. It has
been proposed, though not yet proven, that this chromosomal cpe gene with its two flanking IS1470
sequences corresponds to a transposon [36]. Consistent with that possibility, PCR has detected
circular forms carrying the cpe gene in type A chromosomal cpe strain NCTC8239 that may represent
transposition intermediates [39].
In addition to carrying this putative transposon, chromosomal cpe type A strains are
phylogenetically distinct from other C. perfringens. Helping to explain their strong association with
food poisoning, most chromosomal cpe type A strains produce a variant small acid soluble protein
that binds tightly to spore DNA, which provides these chromosomal cpe strain spores with much
stronger resistance against food environment stresses, such as heating, than exhibited by spores of other
C. perfringens strains [40–42].
The remaining ~30% of type A food poisoning strains, and virtually all CPE-positive type
A non-food-borne human GI disease C. perfringens strains, carry their cpe gene on plasmids of
~70–75 kb [2,43]. In type A strains, all known cpe-positive plasmids belong to either the pCPF5603
or pCPF4969 plasmid families [44]. Both cpe plasmid families in type A strains are thought to have
derived from a common precursor plasmid (a pCP13-like plasmid), but the pCPF5603 plasmid family
now also carries the gene encoding beta2 toxin and a cluster of putative metabolic genes, while the
pCPF4969 plasmid family now also carries a VirS/VirR-like two-component regulatory system and
a putative bacteriocin [44]. Like the chromosomal cpe gene, the plasmid-borne cpe gene in type A
strains is closely associated with insertion sequences, which could mobilize this toxin gene. In both
cpe plasmid families found in type A strains, the cpe gene is flanked by a 51 IS1469 insertion sequence.
However, the cpe gene is usually flanked 31 by IS1470 in pCPF4969 family plasmids but by IS1151 in
pCPF5603 family plasmids [44]. In addition to the close association between insertion sequences and
the plasmid-borne cpe gene of type A strains, these cpe genes may be further mobilized by their presence
on conjugative plasmids [45]. pCPF4969 family plasmids have been shown to conjugatively transfer
among C. perfringens strains, probably due to their carriage of similar tcp sequences demonstrated to
mediate conjugative transfer of other C. perfringens plasmids [45]; pCPF5603 family plasmids are likely
to also be conjugative since they carry similar tcp sequences [44].
In types C, D, and E strains, the cpe gene is also located on plasmids, but these are usually larger
in size than the cpe plasmids of type A strains [46]. In type C strains, the cpe plasmid is usually either
~85 kb or ~110 kb [4]. Interestingly, the plasmid cpe locus in some type C strains closely resembles that
found in pCPF5603 and has both a 51 IS1469 insertion sequence and a 31 IS1151 insertion sequence.
However, the plasmid cpe locus in other type C strains more closely resembles the chromosomal cpe
locus of type A strains with a 31 IS1470 sequence, along with an additional IS1470-like sequence, that is
located upstream of the cpe gene but downstream of the 51 IS1469 element [47]. In type D strains, the
cpe gene can be found on ~75, 85, or 110 kb plasmids. The sequenced cpe loci in type D strains have a
unique genetic organization, with two putative upstream transposase genes similar to Tn1546 and
downstream sequences similar to that found in the cpe plasmid in type A strain F4969; however the
type D cpe locus lacks an IS1470-like insertion sequence [4]. Finally, type E strains of C. perfringens
commonly carry plasmids with the cpe gene or silent cpe sequences. When carrying silent copies of cpe,
those plasmids resemble pCPF5603, but are much larger (~97 or 135 kb) and carry iota toxin genes
that have apparently inserted upstream of their cpe gene, thereby eliminating cpe expression [48]. In
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contrast, a recent study discovered type E strains with an ~65 kb pCPF4969-like plasmid that carries
an expressed copy of cpe [6].
Taken together, the above findings clearly indicate that the cpe gene is present in a diverse range
of C. perfringens strains, where it can reside either on the chromosome (in most food poisoning isolates)
or on a number of different, but often related, conjugative plasmids. In addition, the cpe gene is often
associated with flanking insertion sequences and/or transposases [4,6,36,38,44,48]. This association of
the cpe gene with mobile genetic elements likely assists its mobilization and transfer, thereby impacting
the evolution of virulence in many intestinal disease-causing strains of C. perfringens.
5. CPE Production and Regulation
Regardless of whether it is chromosomally- or plasmid-encoded, the cpe gene is only expressed
during sporulation [2,7], when C. perfringens undergoes asymmetrical cell division under nutritionally
depleted conditions. This process results in the production of a mature spore that is dormant and
can withstand harsh environmental conditions, such as cooking, that are encountered in the food
environment. C. perfringens food poisoning often occurs when the exceptionally-resistant spores of type
A chromosomal cpe strains survive improper cooking and then germinate into vegetatively growing
cells. Those bacteria grow to high numbers in the contaminated food, which is then consumed. If large
numbers of vegetative cells are ingested, some survive the acidity of the stomach and then passage
into the intestine, where they initially expand in numbers. However, once present in the intestine,
these vegetative cells soon commit to sporulation and begin to produce CPE. At the completion
of sporulation, the mother cell lyses, which releases CPE into the intestinal lumen so it can act, as
described later [7].
During non-food-borne CPE-mediated human gastrointestinal disease, spores are thought to be
the actual infectious agent [16], followed by repeated cycles of spore germination and sporulation
(along with CPE production) in the intestine [16]. This cycling may be due to greater colonization
ability by non-food-borne GI disease strains [49] and likely explains the longer duration of these
illnesses compared to C. perfringens type A food poisoning. The presence of the cpe gene on conjugative
plasmids in the non-food-borne GI disease strains may contribute to these illnesses by converting
colonization-proficient, but naturally CPE-negative, normal flora C. perfringens strains to intestinal
virulence [45].
Similarly as sporulation in other Clostridium spp and in Bacillus spp., C. perfringens sporulation
involves a hierarchical cascade of regulation [50,51]. During the in vivo sporulation of C. perfringens,
an unknown signal, possibly the presence of inorganic phosphate or the presence of bile salts, leads
to the activation of the master sporulation regulator Spo0A [52,53]. Studies in other Bacillus and
Clostridium spp. also demonstrated that Spo0A is a response regulator protein whose activity is
dependent on phosphorylation; the phosphorylated Spo0A then binds to regions upstream of genes
required for sporulation. Once bound, phosphorylated Spo0A activates the expression of these
sporulation genes [54]. Using knock-out mutants, it has been established that Spo0A is also required for
C. perfringens to sporulate and produce CPE [55].
Among the target genes that are likely to be activated by phosphorylated Spo0A in C. perfringens
is the gene encoding SigF [50,54]. SigF is an alternative sigma factor that is required for C. perfringens
sporulation and CPE production [50]. Furthermore, using a C. perfringens sigF null strain, it was
shown that SigF regulates production of downstream alternative sporulation-specific sigma factors, i.e.,
SigG, SigK, and SigE, each of which is required for the completion of sporulation in C. perfringens [50].
However, besides SigF (which regulates production of the other three sigma factors), SigK, and SigE
(but not SigG) are required for CPE production [51]. This is explainable by the presence of three
promoters upstream of the cpe gene (whether chromosomal or plasmid) in type A strains that regulate
the expression of cpe [56]. The first of these promoters (P1) contains sequences similar to previously
described SigK recognition sequences, while the second and third promoters (P2 and P3) demonstrate
similarity to recognition sequences for SigE [56]. Taken together, the current model proposes that
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phosphorylated Spo0A activates the transcription of SigF, which then activates the transcription of
SigG, SigK, and SigE, all of which are required for sporulation, with the latter two also required for
CPE production (Figure 3).
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All regulatory factors shown are required for sporulation and all but SigG are also required for CPE
production. CcpA (not shown) also controls CPE production and sporulation through an unknown
pathway [58]. Adapted from [50].
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laudins for the backbone [61] of tight junctions (TJs), hich are located at apical cell-cell
contact regions in epithelial and endothelial cells. Claudins can form fibrils that play important roles
in modulating the structure and function of mammalian TJs [61–63]. The claudin family consists
of 27 different proteins, which typically are 20–27 kDa in size. Claudins are comprised of four
transmembrane domains, a short C-terminal cytoplasmic tail and two extracellular loops (named
ECL-1 and ECL-2) [64].
Toxins 2016, 8, 73 8 of 16
Certain members of the claudin tight-junction protein family are functional receptors for CPE
binding to host cells. Specifically, claudins 3, 4, 6, 8, and 14 are proven CPE receptors [65–68]. However,
not all 27 members of the claudin family are CPE-receptors as claudins 1, 2, 5, and 10 do not bind CPE
at pathophysiologically relevant toxin concentrations [66–69].
Studies using chimeric claudins showed that the ECL-2 region is critical for a claudin to bind
CPE [66]. Peptide mapping studies identified a pentapeptide sequence within the ECL-2 region that is
important for CPE binding [70]. Site-directed mutagenesis showed that an Asn residue located in this
pentapeptide is a critical yes/no determinant for CPE binding, with adjacent residues modulating the
affinity of CPE binding [71] (note that some claudin receptors, like claudin 4, bind CPE very tightly,
while other receptors, such as claudin 8, bind the toxin with less affinity [67]).
Given those findings documenting the importance of CPE:ECL-2 interactions, it was interesting
when recent structural analyses (Figure 2B) revealed that both the ECL-1 and ECL-2 regions of claudin
receptors interact with CPE and that the interactions between ECL-1 and the toxin are also necessary
for binding [34]. The emerging picture is that all claudins can carry out the necessary interactions
between ECL-1 and the CPE binding domain, as supported by studies [65] with chimeric claudins
showing that the N-terminal half (containing the ECL-1 region) can be interchanged between receptor
and non-receptor claudins without affecting CPE binding. However, only the receptor claudins possess
a suitable ECL-2 region for CPE binding [66,71].
Binding of CPE to claudin receptors results in the formation of a „90 kDa, “small complex” that
contains CPE and both receptor and non-receptor claudins (Figure 4) [72,73]. This small complex is, by
itself, insufficient to trigger cytotoxicity; instead, several small CPE complexes interact to promote CPE
oligomerization to form a prepore on the plasma membrane surface [74]. This oligomerization results
in the formation of a ~450 kDa CPE “large complex” named CH-1, that contains a CPE hexamer and
both receptor and non-receptor claudins [72].
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Figure 4. The mechanism of action of C. perfringens ent rotoxin. CPE first binds to claudin receptors
(green boxes) present on the apical surface of host cells and forms a small complex. Several
(approximately six) small complexes, which also contain non-recepto claudin, o shown), interact to
promote CPE oligomerization and form a prepore on the plasma membrane surface. β-hairpins in the
CPE molecules of the prepore then form a β-barrel that ins rts nto membranes to form an active pore
named CH-1. Low-dose CPE treatment causes a limited calcium influx and some cytoplasmic calpain
activation to cause caspase-3 edi t apoptosis. High dose CPE treatment causes a strong calcium
influx cytoplasmic calpain activation to induce cell death via oncosis. Morphologic damage to the cells
exposes the basolateral surface of cells, which allows CPE access to other receptors to form additional
CH-1 complex. Further, this basolateral surface exposure allows for the formation of a second large
complex named CH-2, which triggers internalization of CPE-non receptor occludin and claudin into
the cytoplasm. Modified with permission from [74].
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β-hairpin loops from CPE in the CH-1 complex assemble into a β-barrel that quickly inserts into
membranes to form a pore [30,75], causing plasma membrane permeability alterations in sensitive
mammalian cells [76–79]. The CPE pore is cation permeating [76] and permits a calcium influx that is
important if not essential for CPE-induced cell death [78–82].
Low CPE doses result in formation of a low number of pores, causing a modest calcium
influx [81,82]. Via a process involving calmodulin and a modest calpain activation, this limited
calcium influx triggers a caspase-3 mediated death of the CPE-treated cell with all the hallmarks
(e.g., cytochrome c release) of classical apoptosis. In contrast, higher CPE doses cause formation of
many pores, producing a massive calcium influx [83]. Via a process involving calmodulin and a very
strong calpain activation, this overwhelming calcium influx results in a form of necrotic cell death
known as oncosis [83].
With extended time, morphological damage develops in CPE-treated cells, which exposes the
basolateral cell surface. This allows additional binding of the toxin such that the toxin now forms
an even larger (~600 kDa) complex named CH-2, which contains claudins and occludin [72,84], a
structural component of epithelial TJs. The contribution of CH-2 to cytotoxicity is unclear but it may
help to explain the observed internalization of occludin (and claudins) into CPE-treated cells.
7. CPE in vivo Effects
CPE causes histologic damage in the small intestine of all tested mammalian species, presumably
including humans since the toxin similarly damages human small intestinal tissue ex vivo [15,85–88].
CPE-induced histologic damage includes severe villus shortening, along with epithelial necrosis and
desquamation [15,86–88]. Animal model studies support a role for CPE-induced cytotoxicity in the
development of this histologic damage, i.e., noncytotoxic, but binding-capable, CPE derivatives fail to
cause the development of histologic damage in rabbit small intestines [89]. Further linking the cellular
action of CPE with the toxin’s intestinal effects are observations that CPE first damages villi tips in
rabbit small intestine, which have an abundant presence of the CPE receptor claudin 4 [89] (Figure 5).
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Figure 5. A synthetic peptide corresponding to the ECL-2 region of the claudin 4 CPE receptor can act
as a decoy receptor and interfere with CPE action in vivo. Hematoxylin and Eosin-stained histology
(100ˆ, top; 400ˆ, bottom) shown for: Control (loops treated with buffer alone); CPE + buffer (loops)
treated with CPE and buffer but no synthetic peptide); CPE + Cldn-1 ECL-2 (loops treated with CPE
and a synthetic peptide with the ECL-2 sequence of non-CPE receptor claudin 1); CPE + Cldn-4 ECL-2
(loops treated with CPE and a synthetic peptide with the ECL-2 sequence of CPE receptor claudin 4).
All results are shown after a 1-h incubation. Modified with permission from [90].
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CPE-induced intestinal damage appears to be an important, if not essential, contributor to
CPE-induced fluid and electrolyte secretion. For example, in rabbit small intestinal loops, a close
temporal association exists between the onset of CPE-induced histologic damage and the start of fluid
and electrolyte loss [87]. Furthermore, fluid and electrolyte losses only develop in the small intestines
of animal models treated with CPE doses capable of causing histologic damage [86].
For many years it was believed that CPE had no effect on the colon, despite the ability of this
organ to bind high levels of the enterotoxin due to the presence of receptor claudins [88]. However,
a recent study demonstrated that CPE does induce histologic damage and fluid/electrolyte losses
in the rabbit colon [91]. This result may help to explain the necrotizing colitis observed in a severe
C. perfringens type A food poisoning outbreak that occurred in patients of an Oklahoma psychiatric
facility [13].
As mentioned earlier, studies with CPE-challenged mouse small intestinal loops directly
demonstrated that CPE can be absorbed through the intestines [15]. This appearance of the enterotoxin
in the circulation leads to CPE binding to nonintestinal organs such as the liver and kidneys. Those
interactions lead to a lethal enterotoxemia, largely due to a hyperpotassemia that likely induces cardiac
arrest in these mice [15]. It has been proposed that CPE-induced enterotoxemia could explain the
severity of the previously mentioned C. perfringens type A food poisoning outbreaks in psychiatric
hospitals [13,14]. Those outbreaks involved the deaths of several relatively young and healthy people
with preexisting psychotropic drug-induced constipation or fecal impaction side-effects, which likely
delayed diarrhea and prolonged contact of CPE with the intestines, fostering toxin absorption [14].
8. Potential CPE Vaccine
A series of defined CPE fragments were reacted with a panel of CPE-specific monoclonal
antibodies (MAbs) in epitope mapping studies [28]. Those analyses identified at least four regions,
scattered throughout the enterotoxin protein, that are involved in epitope presentation. A linear
epitope recognized by one anti-CPE MAb, i.e., MAb 3C9, maps to the extreme C-terminal 30 amino
acid region of the enterotoxin. The C-terminal region of CPE is involved in binding of the enterotoxin
to claudins (see Section 3), so the reactivity of MAb 3C9 with an epitope located in this region is fully
consistent with observations that this monoclonal is a neutralizing antibody that blocks CPE receptor
binding [92].
Since C-terminal CPE fragments are not cytotoxic [22,23], the presence of a neutralizing epitope in
those fragments suggested they might be potential CPE vaccine candidates. This possibility was tested
by conjugating a thyroglobulin carrier with a synthetic peptide corresponding to the C-terminal 30
amino acids of CPE [93]. When mice received an intravenous injection of this conjugate, they mounted
a strong CPE-neutralizing antibody response. While this conjugate has vaccine potential, it has not yet
been tested for the ability to stimulate a mucosal IgA response, as would be necessary for intestinal
protection against CPE-mediated disease.
9. Translational Applications of CPE
Many human normal or cancer cells express claudins that can function as CPE receptors.
Exploiting that observation, the CPE protein (or non-cytotoxic CPE derivatives such as C-CPE) are
now being actively explored for a variety of translational applications.
It has become well established that cancer cells, particularly prostate, breast, pancreatic, and
ovarian cancer cells, upregulate their expression of claudin CPE receptors [94]. In response,
considerable effort has been made towards developing CPE-based approaches for cancer therapy and
diagnosis [94]. As an example of animal model studies supporting this application, CPE was shown to
suppress pancreatic tumor growth in mice [95]. Alternatively, a novel therapeutic has been developed
that consist of C-CPE and active agents such as the protein synthesis inhibitory region of Pseudomonas
exotoxin A; those chimeric proteins were demonstrated to selectively damage tumor cells [96].
Another approach used C-CPE to sensitive ovarian cancer cells to treatment with conventional cancer
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therapeutics, including taxol and carboplatin [97]. In addition to treatment, labeled C-CPE-based
derivatives have been used for imaging and detecting tumors [98]. For example, micrometastatic
human ovarian cancer tumor implants in mice have been visualized using fluorescently-labeled
C-CPE [98].
For mucosal immunizations the important first step is delivering the desired antigen to
mucosal-associated lymphoid tissue (MALT). MALT contains multiple cell types, including M cells,
that take up and present antigen to underlying antigen-presenting cells for processing. M cells express
high levels of claudin 4, a high-affinity CPE receptor, so fusion proteins containing the C-CPE claudin
binding domain represent attractive agents for enhancing mucosal immunizations [99]. An example of
several studies exploring this immunization approach used C-CPE fused with pneumococcal surface
protein A (PspA). When administered intranasally, this vaccine induced protective immunity against
challenge with the important bacterial pathogen Streptococcus pneumoniae [99]. Similarly, a peptide
fused to the C-terminal 30 amino acids of CPE has been tested as part of a conjugate vaccine to protect
mice from Coxsackie virus B3 infection [100].
A final translational use of CPE derivatives has been to enhance drug absorption across mucosal
tissue [101]. The rationale for this approach is based upon observations that C-CPE can open tight
junctions, thus increasing drug paracellular permeability. In fact, observations indicate that C-CPE
has ~400-fold more activity than clinically used enhancers of drug delivery [101]. Current efforts
are developing even more potent and specific C-CPE-based drug delivery enhancers by mutagenesis
approaches [24]. For example, engineered C-CPE variants recognizing only one or a few specific
claudins (e.g., claudin 4) can enhance insulin delivery across human nasal epithelial cells [102].
10. Concluding Remarks
The increasing knowledge of CPE action at the molecular level is not only permitting development
of several translational applications, as described in the preceding section, but is also suggesting new
approaches to control CPE-mediated intestinal disease. For example, synthetic peptides corresponding
to the CPE binding region (ECL-2) of the claudin 4 receptor have been shown to specifically interfere
with CPE action in rabbit small intestinal loops [90] (Figure 5). Such agents might prove useful as
therapeutics for treating exceptionally severe cases of CPE-mediated food poisoning or CPE-mediated
non-food-borne diseases, which can be chronic (lasting for multiple days to weeks) and are often more
severe than CPE-mediated food poisoning. CPE also represents an exquisite, increasingly used tool for
probing tight junction structure and function.
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